Shandong Weigao Group Medical Polymer Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Rinan Cong

Chief executive officer

CN¥4.0m

Total compensation

CEO salary percentage	42.1%
CEO tenure	no data
CEO ownership	0.05%
Management average tenure	2.4yrs
Board average tenure	2.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rinan Cong's remuneration changed compared to Shandong Weigao Group Medical Polymer's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥4m	CN¥2m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥5m	CN¥950k	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥3m	CN¥903k	CN¥2b

Compensation vs Market: Rinan's total compensation ($USD551.17K) is about average for companies of similar size in the Hong Kong market ($USD532.18K).

Compensation vs Earnings: Rinan's compensation has been consistent with company performance over the past year.

CEO

Rinan Cong (43 yo)

no data

Tenure

CN¥3,990,000

Compensation

Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jing Long	Executive Chairman of the Board & Compliance Officer	5.9yrs	CN¥8.27m	0.14% HK$ 29.2m
Rinan Cong	Chief Executive Officer	no data	CN¥3.99m	0.048% HK$ 9.9m
Junqiang Lu	Executive Director	2.4yrs	CN¥1.32m	no data
Xue Feng Wu	Chief Financial Officer	7.8yrs	no data	no data
Xia Yan	Non-Executive Director	less than a year	no data	no data
Daoming Wang	Executive Director	less than a year	no data	0.011% HK$ 2.3m
Miu Ling Wong	Company Secretary	18.5yrs	no data	no data

2.4yrs

Average Tenure

49yo

Average Age

Experienced Management: 1066's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jing Long	Executive Chairman of the Board & Compliance Officer	5.9yrs	CN¥8.27m	0.14% HK$ 29.2m
Junqiang Lu	Executive Director	2.4yrs	CN¥1.32m	no data
Xia Yan	Non-Executive Director	less than a year	no data	no data
Daoming Wang	Executive Director	less than a year	no data	0.011% HK$ 2.3m
Lin Chen	Non-Executive Director	3.7yrs	no data	no data
Hong Meng	Independent Non-Executive Director	2.2yrs	CN¥150.00k	no data
Guohui Li	Independent Non-Executive Director	2.4yrs	CN¥207.00k	no data
Zhengpeng Tang	Vice Chairman	3.7yrs	no data	no data
Meijun Gu	Chairman of the Supervisors	4.3yrs	no data	no data
Zhuangqiu Zhang	Employee Representative Supervisor	2.6yrs	no data	no data
Qiang Li	Independent Non-Executive Director	1.9yrs	CN¥150.00k	no data
Heng Sun	Independent Non-Executive Director	less than a year	no data	no data

2.4yrs

Average Tenure

49yo

Average Age

Experienced Board: 1066's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Shandong Weigao Group Medical Polymer Management

Management criteria checks 3/4

Key information

Recent management updates

Shandong Weigao Group Medical Polymer Company Limited Approves Board Appointments

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, May 28, 2024

Shandong Weigao Group Medical Polymer Company Limited Announces the Resignation of Ni Has Tendered as Executive Director, Effective from 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Appoints Li Qiang as an Independent Non-Executive Director

Key Executive recently sold HK$5.8m worth of stock

Less than half of directors are independent

Recent updates

Shandong Weigao Group Medical Polymer Company Limited Approves the Distribution of Interim Dividend for the Six Months Ended 30 June 2024, Payable on 22 November 2024

Investor sentiment deteriorates as stock falls 17%

Upcoming dividend of CN¥0.092 per share

Investor sentiment improves as stock rises 16%

First half dividend of CN¥0.092 announced

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.27 in 1H 2023)

Shandong Weigao Group Medical Polymer Company Limited Proposes an Interim Dividend for the Six Months Ended 30 June 2024, Payable on Before 22 November 2024

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2024 Results on Aug 28, 2024

Shandong Weigao Group Medical Polymer Company Limited Approves Board Appointments

Upcoming dividend of CN¥0.094 per share

Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.61 in FY 2022)

Final dividend of CN¥0.094 announced

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.60 in FY 2022)

Shandong Weigao Group Medical Polymer Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Shandong Weigao Group Medical Polymer Company Limited Provides Earnings Guidance for the Year Ended 31 December 2023

Investor sentiment deteriorates as stock falls 18%

Shandong Weigao Group Medical Polymer Company Limited Announces the Resignation of Ni Has Tendered as Executive Director, Effective from 31 December 2023

Shandong Weigao Group Medical Polymer Company Limited Approves Distribution of Interim Dividend for the Six Months Ended 30 June 2023

Upcoming dividend of CN¥0.073 per share at 2.4% yield

First half 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.34 in 1H 2022)

Shandong Weigao Group Medical Polymer Company Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 24 November 2023

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2023 Results on Aug 29, 2023

Now 21% undervalued after recent price drop

Shandong Weigao Group Medical Polymer Company Limited Approves Final Dividend for the Year Ended 31 December 2022, Payable on or Before 14 July 2023

Upcoming dividend of CN¥0.079 per share at 1.5% yield

Full year 2022 earnings released: EPS: CN¥0.60 (vs CN¥0.51 in FY 2021)

Shandong Weigao Group Medical Polymer Company Limited Appoints Li Qiang as an Independent Non-Executive Director

Key Executive recently sold HK$5.8m worth of stock

Now 22% undervalued

Less than half of directors are independent

Shandong Weigao Group Medical Polymer Company Limited Announces Resignation of Wang Jinxia as an Independent Non-Executive Director of the Company, A Member of Audit Committee, A Member of Remuneration Committee, A Member of Nomination Committee and A Member of Corporate Governance Committee

Now 20% undervalued

Shandong Weigao Group Medical Polymer Company Limited Approves Interim Dividend for the Six Months Ended June 30, 2022, Payable on November 11, 2022

Upcoming dividend of CN¥0.086 per share

Shandong Weigao Group Medical Polymer Company Limited (SEHK:1066) agreed to acquire Weihai Weigao Medical Materials Company Limited from Weigao Holding Company Limited for approximately RMB288.0 million.

First half 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.27 in 1H 2021)

Shandong Weigao Group Medical Polymer Company Limited Announces Executive Changes

Shandong Weigao Group Medical Polymer Company Limited to Report First Half, 2022 Results on Aug 22, 2022

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Executive Appointments

Upcoming dividend of CN¥0.065 per share

Now 22% undervalued after recent price drop

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.47 in FY 2020)

Less than half of directors are independent

Shandong Weigao Group Medical Polymer Company Limited Announces Executive Resignations

Shandong Weigao Group Medical Polymer Company Limited, Annual General Meeting, Jun 06, 2022

Full year 2021 earnings released: EPS: CN¥0.50 (vs CN¥0.45 in FY 2020)

Shandong Weigao Group Medical Polymer Company Limited Recommends Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited to Report Q4, 2021 Results on Mar 29, 2022

Upcoming dividend of CN¥0.077 per share

First half 2021 earnings released: EPS CN¥0.27 (vs CN¥0.22 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shandong Weigao Group Medical Polymer Company Limited Approves Final Dividend for the Year Ended December 31, 2020 At the Annual General Meeting Held on May 24, 2021

Upcoming dividend of CN¥0.068 per share

Full year 2020 earnings released: EPS CN¥0.45 (vs CN¥0.41 in FY 2019)

Chairman & Compliance Officer Hua Wei Zhang has left the company

Executive Vice Chairman Yi Wang has left the company

Shandong Weigao Group Medical Polymer Company Limited Approves the Appointment of Tang Zheng Peng as a Non-Executive Director of the Company

New 90-day low: HK$13.28

Shandong Weigao Group Medical Polymer Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Chairman & Compliance Officer recently sold HK$14m worth of stock

New 90-day high: HK$17.06

Shandong Weigao Group Medical Polymer Company Limited Announces Director Changes

New 90-day low: HK$14.22

New 90-day low: HK$14.82